Surface Phenotype of GL From LDGL Patients Reported in This Study
| Case No. . | CD3 (Leu-4) . | CD4 (Leu-3) . | CD8 (Leu-2) . | CD16 (KD1) . | TCR αβ (WT31) . | TCR γδ (TCR δ1) . | IL-2R* . | ||
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | α Chain . | β Chain . | γ Chain . |
| 1 | + | − | + | + | + | − | − | + | + |
| 2 | + | − | + | + | + | − | − | + | + |
| 3 | + | − | + | + | + | − | − | + | + |
| 4 | + | − | + | + | + | − | − | + | + |
| 5 | + | − | + | + | + | − | − | + | + |
| 6 | + | − | + | + | + | − | − | + | + |
| 7 | + | − | + | + | + | − | − | + | + |
| 8 | + | + | + | + | + | − | − | + | + |
| 9 | + | − | − | + | − | + | − | + | + |
| 10 | − | − | − | + | − | − | − | + | + |
| 11 | − | − | − | + | − | − | − | + | + |
| 12 | − | − | − | + | − | − | − | + | + |
| 13 | − | − | − | + | − | − | − | + | + |
| 14 | − | − | − | + | − | − | − | + | + |
| Case No. . | CD3 (Leu-4) . | CD4 (Leu-3) . | CD8 (Leu-2) . | CD16 (KD1) . | TCR αβ (WT31) . | TCR γδ (TCR δ1) . | IL-2R* . | ||
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | α Chain . | β Chain . | γ Chain . |
| 1 | + | − | + | + | + | − | − | + | + |
| 2 | + | − | + | + | + | − | − | + | + |
| 3 | + | − | + | + | + | − | − | + | + |
| 4 | + | − | + | + | + | − | − | + | + |
| 5 | + | − | + | + | + | − | − | + | + |
| 6 | + | − | + | + | + | − | − | + | + |
| 7 | + | − | + | + | + | − | − | + | + |
| 8 | + | + | + | + | + | − | − | + | + |
| 9 | + | − | − | + | − | + | − | + | + |
| 10 | − | − | − | + | − | − | − | + | + |
| 11 | − | − | − | + | − | − | − | + | + |
| 12 | − | − | − | + | − | − | − | + | + |
| 13 | − | − | − | + | − | − | − | + | + |
| 14 | − | − | − | + | − | − | − | + | + |
BB10, TU27, and TUGh4 MoAbs were used to detect IL-2R α, β, and γ chains, respectively. The percentage of cells expressing the IL-2R β chain ranged from 68% to 93% (mean, 84%); the percentage of cells expressing the IL-2R γ chain ranged from 79% to 99% (mean, 89%).